Cost–utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting

被引：0
|
作者：
Shanshan Hu
Yilai Wu
Jiajie Luan
Shuowen Wang
Guorong Fan
机构：
[1] Shanghai General Hospital,Department of Clinical Pharmacy
[2] Shanghai Jiao Tong University School of Medicine,Department of Pharmacy
[3] The First Affiliated Hospital of Wannan Medical College,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷
关键词：
Cost–utility analysis; HER2-positive metastatic breast; Trastuzumab deruxtecan; Trastuzumab emtansine; Price exploring;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：17933 / 17942
页数：9
相关论文
共 50 条
  • [31] Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan
    Pourjamal, Negar
    Le Joncour, Vadim
    Vereb, Gyorgy
    Honkamaki, Cilla
    Isola, Jorma
    Leyton, Jeffrey, V
    Laakkonen, Pirjo
    Joensuu, Heikki
    Barok, Mark
    TRANSLATIONAL ONCOLOGY, 2025, 53
  • [32] Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
    Modi, Shanu
    Saura, Cristina
    Yamashita, Toshinari
    Park, Yeon Hee
    Kim, Sung-Bae
    Tamura, Kenji
    Andre, Fabrice
    Iwata, Hiroji
    Ito, Yoshinori
    Tsurutani, Junji
    Sohn, Joohyuk
    Denduluri, Neelima
    Perrin, Christophe
    Aogi, Kenjiro
    Tokunaga, Eriko
    Im, Seock-Ah
    Lee, Keun Seok
    Hurvitz, Sara A.
    Cortes, Javier
    Lee, Caleb
    Chen, Shuquan
    Zhang, Lin
    Shahidi, Javad
    Yver, Antoine
    Krop, Ian
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07): : 610 - 621
  • [33] Trastuzumab-Deruxtecan in the Therapy of HER2-positive Breast Cancer
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (06) : 365 - 365
  • [34] Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
    Antonarelli, G.
    Corti, C.
    Salimbeni, B. T.
    Tarantino, P.
    Zagami, P.
    Marra, A.
    Trapani, D.
    Tolaney, S.
    Cortes, J.
    Curigliano, G.
    ESMO OPEN, 2023, 8 (04)
  • [35] A COST-EFFECTIVESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE BREAST CANCER IN PORTUGAL
    Silva Miguel, L.
    Pinheiro, B.
    Lopes, R.
    Revil, C.
    Monteiro, I
    Borges, M.
    VALUE IN HEALTH, 2022, 25 (01) : S69 - S70
  • [36] HER2-positive metastatic Breast Cancer Trastuzumab Emtansine: First Choice for the Second Line
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (11) : 744 - 744
  • [37] Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial
    Khattak, Monica N.
    Chichura, Anna M.
    Lang, Julie E.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (03) : 1423 - 1427
  • [38] Trastuzumab-deruxtecan and blood inflammatory markers in HER2-positive metastatic breast cancer
    Onishi, Mai
    Shimoi, Tatsunori
    Kitadai, Rui
    Tokura, Momoko
    Yazaki, Shu
    Sumiyoshi-Okuma, Hitomi
    Arakaki, Motoko
    Saito, Ayumi
    Kita, Syosuke
    Yamamoto, Kasumi
    Maejima, Aiko
    Kojima, Yuki
    Nishikawa, Tadaaki
    Sudo, Kazuki
    Noguchi, Emi
    Fujiwara, Yasuhiro
    Yonemori, Kan
    ANNALS OF ONCOLOGY, 2023, 34 : S1423 - S1423
  • [39] Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial
    Monica N. Khattak
    Anna M. Chichura
    Julie E. Lang
    Annals of Surgical Oncology, 2024, 31 : 1423 - 1427
  • [40] Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?
    Roodhart, Jeanine M. L.
    Koopman, Miriam
    LANCET ONCOLOGY, 2024, 25 (09): : 1104 - 1105
12345